We conducted an animal experiment to assess the effect of adding pentoxifylline to amikacin to prevent amikacin-induced 
Introduction
Amikacin, a semisynthetic first derivative of aminoglycoside, is made from the natural drug kanamycin by acylation. 1 It is resistant to bacterial enzymes that can inactivate other natural aminoglycosides such as gentamicin, tobramycin, and kanamycin. 2 Amikacin is cochleotoxic because it produces reactive oxygen species or free oxygen radicals, which results in apoptosis, which in turn causes ototoxicity and deafness. 3, 4 Various methods have been proposed for preventing aminoglycoside-induced ototoxicity, and results have been variable.
Otoacoustic emissions (OAEs) were first reported by Kemp in 1987 . 5 When sound is introduced within a normal-hearing and -functioning cochlea, the stereocilia of the outer hair cells are stimulated, and they change their shape to amplify and propagate specific sounds along the basilar membrane. This process is referred to as an electromotile response. In mammals, the electromotile response occurs essentially as a result of the conversion of electrical energy into mechanical energy. 6 In clinical practice, the most common OAEs recorded are transient evoked OAEs (TEOAEs) and distortion product OAEs (DPOAEs). Kramer noted that TEOAEs are recorded during the silent intervals between brief broad-spectrum transient clicks, which activate a wide portion of the basilar membrane. 7 TEOAEs can be measured between 1.0 and 4.0 kHz. 7 An acceptable TEOAE is usually 3 to 6 dB above the noise floor and is reproducible. If a reproducible response is not evident at a signal-to-noise ratio of 3 dB or more, we can assume that the outer hair cells of that frequency region are not functioning normally. 7 Because the cochlea is nonlinear, distortion occursthat is, some sounds generated within the cochlea are not externally presented. Specifically, when two pure tones (assume primary tone f1 is lower in frequency and primary tone f2 is higher in frequency) are presented to the human ear at the same time, the most prominent distortion product occurs at 2f1-f2-the cubic difference tone. 8 While TEOAEs are recorded after and between click presentations, DPOAEs are recorded during cochlear activation. DPOAEs are typically recorded from 1.0 to 6.0 kHz. The DPOAE reflects the status of the cochlea at the representative cubic difference tone, not the primary tones. 7 DPOAEs have been recorded in many laboratory animals, but efforts to record TEOAEs have not succeeded much in nonprimate mammals other than guinea pigs. However, TEOAEs have been unequivocally registered in every rat ear studied by using short pulses (40 μsec) to generate the clicks and a short (1.1 msec) amplifier gain suppression period, as reported by Khvoles et al. 9 The responses were reproducible in the same rat above the noise floor, and they disappeared postmortem. They were shorter in duration in rats than in guinea pigs, and they were made up of a broad-band frequency spectrum between 2.0 and 4.0 kHz.
Postmortem, the TEOAEs to 65 dB SPL clicks disappeared at about the same time as the DPOAEs to low-stimulus intensities and before the DPOAEs to high-stimulus intensities. So, after refining the technique, based on the use of short clicks and a short amplifier gain suppression period, TEOAEs have been recorded on the same instrumentation and with the same techniques used for studying rabbits, mice, rats, and guinea pigs.
In this article, we describe our investigation of the possible protective effect of pentoxifylline in amikacin-induced ototoxicity in an animal model.
Materials and methods

Subjects.
We used adult male Wistar rats obtained from the Egyptian National Research Laboratory that were kept in colony cages with free access to food and tap water and under standardized housing conditions (natural light-dark cycle, temperature of 22 ± 1°C). The animals were examined by otoscopy, and those with signs of an external ear disorder (e.g., hyperemia, edema, a tumor, or impacted earwax) or middle ear disorder (e.g., tympanic membrane opacification, bulging, hyperemia, or perforations) and those with absent TOAEs were excluded from the study.
The 6-week-old rats were examined and weighed; their average weight was 130 ± 10 g. OAEs were absent in almost all of them. The rats were kept for 1 month until they gained weight (mean: 180 ± 10 g). The TEO-AE test was performed again and rats with significant TEOAE amplitudes obtained in two or more frequency bands were included in the experiment.
Anesthesia. Before TOAEs were recorded, all rats were anesthetized with 50 mg/kg of intraperitoneal ketamine and 5 mg/kg of intraperitoneal xylazine as described by Struck et al.
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Experiment design. The animals were divided into four groups of 6 and treated as follows:
• One group was injected with 200 mg/kg of intramuscular amikacin once daily for 14 days (AMK-only group).
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• Another group received 25 mg/kg of oral pentoxifylline dissolved in saline via gastric lavage 12 and 200 mg/kg of intramuscular amikacin once daily for 14 days (PTX-AMK 14/14 group).
• A third group received 25 mg/kg of oral pentoxifylline dissolved in saline via gastric lavage for 28 days and 200 mg/kg of intramuscular amikacin once daily for 14 days on days 15 to 28 of the pentoxifylline regimen (PTX-AMK 28/14 group).
• A control group was administered 1 ml/day of 0.5% carboxymethyl cellulose for 28 days.
We observed no differences in the consumption of water or food among the groups. The rats tolerated the anesthesia, pentoxifylline, amikacin, and saline administrations.
TOAE measurements were performed on all rats on day 0 (immediately before drug administration) and day 14 using the smallest available probe (ILO V6 Clinical OAE software; Otodynamics; Hatfield, U.K.). Differences in the TOAEs as a measure of cochlear activity among the four groups were statistically analyzed.
TEOAE parameters. Nonlinear click stimulation was used for clinical documentation of TEOAEs. A plain click stimulus (80-μsec drive signal) is repeated 50 times per second, resulting in a 20-msec response window. The nonlinear TEOAE type is used because it provides much greater immunity from stimulus artifact contamination. Stimulus level ranges at 84 ± 3 dB pe. A low-cut filter was used to help in the collection of data in a noisy situation.
Blood samples obtained from retrobulbar veins were withdrawn from all rats for the measurement of serum urea and creatinine levels. These levels were measured by the colorimetric quantitative determination method with the use of a diagnostic kit (Diamond Diagnostics; Zagazig, Egypt), according to the principle developed by Henry et al.
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Ethical considerations. All experimental protocols were approved by the Ethics Committee of Zagazig University.
Results
Before treatment, we evaluated TEOAE values as a measure of cochlear activity among the four groups and found no statistically significant differences among them (table 1) . Saline administration resulted in no significant changes in measured TEOAEs.
A comparison of the TEOAE amplitudes before and after treatment revealed that TEOAEs disappeared in all frequency bands after treatment in both the AMK-only group and the PTX-AMK 14/14 group. This suggests that pentoxifylline administration for 14 days did not prevent amikacin-induced ototoxicity. However, when pentoxifylline was administered for a longer period (28 days) starting 2 weeks before amikacin administration (i.e., PTX-AMK 28/14 group), a significant protective influence was noted for pentoxifylline (table 2) .
Combining the results in the two PTX-AMK groups as a mean (±SD) would have biased our findings because some rats had low emissions (nonsignificant) and others had emissions that were significantly above the noise floor. Therefore, we chose to describe our results qualitatively as those emissions that were significantly above the noise floor (i.e., present) and those that were low (i.e., absent) (table 3) .
Mean serum urea and creatinine levels in the PTX/ AMK 14/14 group were significantly lower than those of the AMK-only group, and the levels in the PTX/AMK 28/14 group were significantly lower than the levels in the other two treatment groups (p < 0.05 for all), but not significantly different from those of the control group (table 4) .
Discussion
Aminoglycosides are potent antibiotics that can cause toxic effects to the kidneys and inner ear. While the damage to the kidney is usually reversible, damage to the inner ear is permanent. 4 That is why the therapeutic use of aminoglycosides is risky.
1 Inside the hair cell, aminoglycosides cause damage, either directly or indirectly, by first inducing disarray in the stereocilia, which ultimately culminates in apoptotic cell death.
The presence of aminoglycosides within hair cells leads to an increase in the formation of reactive oxygen species or free oxygen radicals. 3, 4 Damage to the organ of Corti initially begins at the outer hair cells of the basal turn and progresses toward the cochlear apex. 1 Amikacin is one of the aminoglycoside drugs that are used widely because of their powerful efficacy, rapid bactericidal activity, and low cost-despite some serious side effects (i.e., ototoxicity and nephrotoxicity). Amikacin is used for the treatment of severe infections, especially when a synergistic action is required. 13 After injection, amikacin permeates the inner ear fluid and can damage the hair cells. 14 Typically, the ototoxic effect of amikacin is sensorineural, nonsyndromic, bilateral, and progressive, and it affects the higher frequencies. The reported incidence of amikacin-induced ototoxicity has ranged between 10 and 80%. 13 The DPOAE test is a noninvasive, objective, and extraordinarily sensitive method for evaluating outer hair cell function and detecting cochlear damage. It is used to monitor patients for drug-induced ototoxicity. 15 We used the TEOAE test in our study because it allowed us to measure emissions in all rats before treatment. 16 The rats were tested before treatment to ensure a uniform breeding environment and an absence of any concomitant variable that might have affected their cochleae.
The amplitude of TEOAEs was statistically insignificant. All the rats on amikacin in our study lost their emissions after treatment for 14 consecutive days. This finding is in concordance with that of Sockalingam et al, who reported that outer hair cells are primary targets for ototoxic drugs. 17 Moreover, Vu et al reported that aminoglycosides enter the inner ear sensory cells via a mechanically gated ion channel, novel to the sensory hair cells, which is responsible for converting sound waves into electrical signals. 18 They studied genetically engineered mice lacking a critical tip link protein required for mechanotransduction channel activation. Without this link, the channels remain closed. They found that aminoglycosides cannot enter these mutant hair cells and that the hair cells were insensitive to ototoxic agents. In their study, they used a chemical reagent to disrupt these tip links in cultured hair cells and confirmed that the cultured hair cells were protected. They also found that the hair cells became susceptible to toxicity again after the tip links regenerated.
In our study, 14 days of treatment with pentoxifylline did not protect the inner ears of the rats. This differs from the results of Berkiten et al, who measured the DPOAE amplitude levels (dB SPL) before and after treatment at frequencies of 4.0, 6.0, and 8.0 kHz in three groups of rats. 11 They found that the values in their amikacin-only group had dropped significantly by the end of treatment. In contrast, they found no significant differences between pre-and post-treatment values in their amikacin-pentoxifylline group and control group. They concluded that pentoxifylline has protective effects on hearing functions in amikacin-induced ototoxicity in rats. However, they used DPOAE testing, which cannot detect hearing loss at levels where TEOAE can.
In general, when hearing loss is greater than 35 dB HL, TEOAEs will most often be absent. In an important finding, it was determined that when all pure-tone hearing thresholds are better than 20 dB HL, TEOAEs are present 99% of the time. 19 On the other hand, when all pure-tone hearing thresholds are greater than 40 dB HL, TEOAEs are always absent.
DPOAEs are expected to be present if all pure-tone thresholds are better than 25 dB HL, and they are expected to be absent when all pure-tone hearing thresholds are worse than 40 dB HL. However, DPOAEs may be present in reduced amplitudes consistent with hearing thresholds of 50 or 60 dB HL when higher-level primary tones are used. 7 The results of our work revealed that 28 days of pentoxifylline treatment had a protective effect against amikacin ototoxicity. This protective effect might take several weeks to be realized, so we should try to start pentoxifylline for a certain period before amikacin is administered or to extend the use of pentoxifylline after we stop amikacin. As mentioned, the results of our study parallel those of Berkiten et al, who also found that pentoxifylline exerted protective effects against amikacin-induced ototoxicity in rats. 11 The nephrotoxic effect of aminoglycosides is the result of proximal tubule injury leading to cell necrosis. Aminoglycosides, which are strongly cationic drugs, bind to the negatively charged acidic phosphoinositide components of the brush border membrane of the proximal tubule, and several intracellular processes are disrupted. 20 In our study, administration of amikacin elevated the levels of urea and creatinine, but administration of pentoxifylline for 14 days with amikacin reduced those elevated levels in relation to amikacin alone. Continuing the administration of pentoxifylline for another 14 days after amikacin returned the urea and creatinine levels to normal. The cochlea and kidney have similar physiologic mechanisms, including the active transport of fluid and electrolytes via the stria vascularis and glomerulus. They also have many similarities at their ultrastructural level, and they might have a common antigenicity. So both organs are involved in disturbances of body-fluid homeostasis, immunologic factors, and genetic factors such as Alport syndrome and branchiootorenal syndrome. The cochleae and kidneys are affected similarly by some medications (i.e., the nephrotoxic and ototoxic effects of aminoglycosides). 21 Our results are consistent with those of Stojiljkovic et al, 22 who proposed that pentoxifylline has renoprotective effects secondary to its vascular decongestion effect, and Ozer et al, 23 who showed that pentoxifylline inhibits the production of cytokines such as tumor necrosis factor alpha (TNF-α). Other studies have found that pentoxifylline has protective effects on chemotherapy-induced nephrotoxicity and amikacin-induced nephrotoxicity. 24 The otorenoprotective effect of pentoxifylline might be attributable to the inhibition of arachidonic acid metabolism and the decrease of proinflammatory mediators such as TNF-α. TNF-α plays a role in the activation of macrophages and in increasing the proinflammatory secretion of neutrophils, resulting in the stimulation of apoptosis. These effects trigger cell death, resulting in necrosis of target organs. Pentoxifylline is an antioxidant and a free-radical scavenger that decreases free oxygen radicals and nitric oxide synthase. 25 Although many studies have examined the prevention of aminoglycoside-induced ototoxicity, no agent had been proposed for routine use for this purpose. Further histopathologic and clinical studies are needed to evaluate the use of pentoxifylline as an otorenoprotective therapy during treatment with amikacin and other aminoglycosides.
